✦ LIBER ✦

Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants

✍ Scribed by Ashkenazi-Hoffnung, Liat; Dotan, Miri; Livni, Gilat; Amir, Jacob; Bilavsky, Efraim

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Palivizumab for respiratory syncytial vi

✍ Jennifer H. Lofland; Suzanne M. Touch; John P. O'Connor; Mary Lou Chatterton; El 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 890 KB

Palivizumab, a Humanized Respiratory Syn

📂 Article 📅 1998 🏛 American Academy of Pediatrics 🌐 English ⚖ 340 KB

Cost-Effectiveness Of Prophylaxis Of Res

✍ Rosselli, D.; Rueda, J.D.; Ruiz, J.G. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Prophylaxis with palivizumab against res

✍ Jan Sunnegårdh 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Cost-Effectiveness Analysis of Palivizum

✍ Langenfeld, M.K.; Visser, S. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

PIN35 COST-EFFECTIVENESS ANALYSIS OF PAL

✍ S Ikeda; M Kobayashi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB